首页> 美国卫生研究院文献>Respiratory Research >Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma and targeting it for asthma treatment with interleukin-4 receptor antagonists
【2h】

Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma and targeting it for asthma treatment with interleukin-4 receptor antagonists

机译:Th2细胞因子与哮喘-白细胞介素4:在哮喘的发病机制中的作用并将其作为白细胞介素4受体拮抗剂治疗哮喘的靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Interleukin-4 (IL-4) mediates important pro-inflammatory functions in asthma including induction of the IgE isotype switch, expression of vascular cell adhesion molecule-1 (VCAM-1), promotion of eosinophil transmigration across endothelium, mucus secretion, and differentiation of T helper type 2 lymphocytes leading to cytokine release. Asthma is a complex genetic disorder that has been linked to polymorphisms in the IL-4 gene promoter and proteins involved in IL-4 signaling. Soluble recombinant IL-4 receptor lacks transmembrane and cytoplasmic activating domains and can therefore sequester IL-4 without mediating cellular activation. We report the results of initial clinical trials, which demonstrate clinical efficacy of this naturally occurring IL-4 antagonist as a therapeutic agent in asthma.
机译:白介素4(IL-4)介导哮喘中重要的促炎功能,包括诱导IgE同种型转换,表达血管细胞粘附分子1(VCAM-1),促进嗜酸性粒细胞跨内皮转运,黏液分泌和分化导致细胞因子释放的2型T辅助细胞的数量。哮喘是一种复杂的遗传疾病,已与IL-4基因启动子的多态性和与IL-4信号传导有关的蛋白质有关。可溶性重组IL-4受体缺乏跨膜和胞质激活域,因此可以隔离IL-4而无需介导细胞激活。我们报告了初步临床试验的结果,这些结果证明了这种天然存在的IL-4拮抗剂作为哮喘治疗剂的临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号